Health · 1 sources covering this

STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug
STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d955fb595af18a99ced07bd754fd62af31275331"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug"></iframe>

STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

How 1 sources are covering this

STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

More from Health

Rand Paul released Fauci's pandemic-era 'diary.' Now they'll face off on Capitol Hill

Uninsured but Undaunted, a Surgical Patient Searched the Globe for a Deal

Trump Has Quietly Throttled an Agency Devoted to the Safety of American Healthcare

Hospice’s Bad Reputation Amid Fraud Crisis Will Hurt Patients, Industry Experts Warn

Reader

Trust & legal

Across the network